Long-Term Follow-Up Study of Patients who were Treated with Lethally-Irradiated GM-CSF–Transduced Allogeneic Prostate Cancer Cell Vaccine (Prostate GVAX)
To follow-up with subjects who received a gene therapy that is to be evaluated once per year, To identify and characterize any potential long-term adverse events that may be associated with this therapy
All research subjects who have participated in clinical trials of Prostate GVAX, are declared off-study from an interventional clinical trial of Prostate GVAX, must have received at least one dose of the Prostate GVAX vaccine at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.
Visits to the clinic one year after the last dose of GVAX for Physical exam, blood work and potential CT or bone scans and continuing annually for a total of 3 annual visits.
04/19/2014 04:02 AM